Shanghai Pioneer Holding Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 1/6
Shanghai Pioneer Holding hat ein durchschnittliches jährliches Gewinnwachstum von 26% verzeichnet, während die Branche Healthcare ein Gewinnwachstum gewachsen unter 5.1% jährlich einen Rückgang. Die Umsätze sind gewachsen mit einer durchschnittlichen Rate von 3.1% pro Jahr. Shanghai Pioneer Holding's return on equity is 12.7%, und die Nettomargen betragen 9.3%.
Wichtige Informationen
26.0%
Wachstumsrate der Gewinne
26.9%
EPS-Wachstumsrate
| Healthcare Wachstum der Industrie | 11.3% |
| Wachstumsrate der Einnahmen | 3.1% |
| Eigenkapitalrendite | 12.7% |
| Netto-Marge | 9.3% |
| Letzte Ertragsaktualisierung | 31 Dec 2023 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
Shanghai Pioneer Holding's (HKG:1345) Dividend Will Be CN¥0.024
Apr 24
Shanghai Pioneer Holding (HKG:1345) Will Pay A Dividend Of CN¥0.024
Apr 03Shanghai Pioneer Holding's (HKG:1345) Shareholders Have More To Worry About Than Only Soft Earnings
Apr 01Shanghai Pioneer Holding Ltd (HKG:1345) Could Be Riskier Than It Looks
Mar 22Shanghai Pioneer Holding (HKG:1345) Is Finding It Tricky To Allocate Its Capital
Feb 26Does Shanghai Pioneer Holding (HKG:1345) Have A Healthy Balance Sheet?
Oct 21Shanghai Pioneer Holding (HKG:1345) Has Announced That It Will Be Increasing Its Dividend To CN¥0.024
Sep 18Shanghai Pioneer Holding (HKG:1345) Is Increasing Its Dividend To CN¥0.024
Sep 01Here's Why We Think Shanghai Pioneer Holding (HKG:1345) Is Well Worth Watching
Aug 09Shanghai Pioneer Holding's (HKG:1345) Shareholders Will Receive A Smaller Dividend Than Last Year
Apr 14Shanghai Pioneer Holding's (HKG:1345) Shareholders Will Receive A Smaller Dividend Than Last Year
Mar 31Shanghai Pioneer Holding (HKG:1345) Seems To Use Debt Rather Sparingly
Dec 15China Pioneer Pharma Holdings' (HKG:1345) Dividend Will Be Reduced To CN¥0.018
Sep 21China Pioneer Pharma Holdings' (HKG:1345) Shareholders Will Receive A Smaller Dividend Than Last Year
Sep 02China Pioneer Pharma Holdings (HKG:1345) Has More To Do To Multiply In Value Going Forward
Jun 22China Pioneer Pharma Holdings (HKG:1345) Has Announced That Its Dividend Will Be Reduced To HK$0.064
Apr 14China Pioneer Pharma Holdings (HKG:1345) Will Be Hoping To Turn Its Returns On Capital Around
Jan 16These 4 Measures Indicate That China Pioneer Pharma Holdings (HKG:1345) Is Using Debt Safely
Oct 11China Pioneer Pharma Holdings (HKG:1345) Is Paying Out Less In Dividends Than Last Year
Sep 15China Pioneer Pharma Holdings (HKG:1345) Has Announced That Its Dividend Will Be Reduced To HK$0.056
Sep 01China Pioneer Pharma Holdings (HKG:1345) Will Be Looking To Turn Around Its Returns
Aug 26Returns On Capital At China Pioneer Pharma Holdings (HKG:1345) Paint A Concerning Picture
May 22We Think China Pioneer Pharma Holdings (HKG:1345) Can Stay On Top Of Its Debt
Apr 25Can Mixed Financials Have A Negative Impact on China Pioneer Pharma Holdings Limited's 's (HKG:1345) Current Price Momentum?
Mar 14How Has China Pioneer Pharma Holdings (HKG:1345) Allocated Its Capital?
Feb 21
Should You Use China Pioneer Pharma Holdings' (HKG:1345) Statutory Earnings To Analyse It?
Feb 03Is China Pioneer Pharma Holdings Limited (HKG:1345) At Risk Of Cutting Its Dividend?
Jan 16China Pioneer Pharma Holdings (HKG:1345) Has A Rock Solid Balance Sheet
Dec 29Is China Pioneer Pharma Holdings Limited's (HKG:1345) Stock Price Struggling As A Result Of Its Mixed Financials?
Dec 14China Pioneer Pharma Holdings (HKG:1345) Has Gifted Shareholders With A Fantastic 124% Total Return On Their Investment
Nov 29Aufschlüsselung der Einnahmen und Ausgaben
Wie Shanghai Pioneer Holding Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 31 Dec 23 | 1,567 | 146 | 535 | 0 |
| 30 Sep 23 | 1,600 | 168 | 549 | 0 |
| 30 Jun 23 | 1,634 | 190 | 564 | 0 |
| 31 Mar 23 | 1,595 | 213 | 556 | 0 |
| 31 Dec 22 | 1,556 | 235 | 548 | 0 |
| 30 Sep 22 | 1,482 | 216 | 551 | 0 |
| 30 Jun 22 | 1,408 | 196 | 555 | 0 |
| 31 Mar 22 | 1,422 | 169 | 570 | 0 |
| 31 Dec 21 | 1,435 | 143 | 585 | 0 |
| 30 Sep 21 | 1,415 | 117 | 594 | 0 |
| 30 Jun 21 | 1,395 | 91 | 602 | 0 |
| 31 Mar 21 | 1,364 | 72 | 569 | 0 |
| 31 Dec 20 | 1,332 | 52 | 535 | 0 |
| 30 Sep 20 | 1,325 | 45 | 523 | 0 |
| 30 Jun 20 | 1,318 | 37 | 512 | 0 |
| 31 Mar 20 | 1,317 | 71 | 527 | 0 |
| 31 Dec 19 | 1,316 | 105 | 541 | 0 |
| 30 Sep 19 | 1,304 | 84 | 531 | 0 |
| 30 Jun 19 | 1,293 | 63 | 521 | 0 |
| 31 Mar 19 | 1,459 | 74 | 502 | 0 |
| 31 Dec 18 | 1,624 | 85 | 483 | 0 |
| 30 Sep 18 | 1,851 | 171 | 473 | 0 |
| 30 Jun 18 | 2,077 | 258 | 463 | 0 |
| 31 Mar 18 | 2,116 | 269 | 450 | 0 |
| 31 Dec 17 | 2,154 | 279 | 437 | 0 |
| 30 Sep 17 | 2,083 | 279 | 419 | 0 |
| 30 Jun 17 | 2,012 | 280 | 401 | 0 |
| 31 Mar 17 | 1,901 | 259 | 376 | 0 |
| 31 Dec 16 | 1,790 | 237 | 351 | 0 |
| 30 Sep 16 | 1,627 | 174 | 297 | 0 |
| 30 Jun 16 | 1,464 | 111 | 243 | 0 |
| 31 Mar 16 | 1,462 | 143 | 223 | 0 |
| 31 Dec 15 | 1,461 | 174 | 202 | 0 |
| 30 Sep 15 | 1,533 | 231 | 208 | 0 |
| 30 Jun 15 | 1,605 | 287 | 213 | 0 |
| 31 Mar 15 | 1,573 | 274 | 210 | 0 |
| 31 Dec 14 | 1,540 | 262 | 208 | 0 |
| 30 Sep 14 | 1,500 | 262 | 184 | 0 |
| 30 Jun 14 | 1,460 | 263 | 161 | 0 |
| 31 Mar 14 | 1,366 | 250 | 148 | 0 |
| 31 Dec 13 | 1,272 | 238 | 135 | 0 |
| 30 Sep 13 | 1,175 | 229 | 132 | 0 |
| 30 Jun 13 | 1,077 | 220 | 129 | 0 |
Qualität der Erträge: 1345 einen hohen Anteil an unbarem Gewinn hat.
Wachsende Gewinnspanne: 1345Die aktuellen Gewinnspannen (9.3%) sind niedriger als im letzten Jahr (15.1%).
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: 1345In den letzten 5 Jahren sind die Einnahmen von 26% pro Jahr erheblich gestiegen.
Beschleunigtes Wachstum: 1345Das Unternehmen hat im vergangenen Jahr ein negatives Gewinnwachstum verzeichnet, so dass es nicht mit seinem 5-Jahres-Durchschnitt verglichen werden kann.
Erträge im Vergleich zur Industrie: 1345 hatte im vergangenen Jahr ein negatives Gewinnwachstum (-38.1%), was einen Vergleich mit dem Branchendurchschnitt Healthcare (2.2%) erschwert.
Eigenkapitalrendite
Hohe Eigenkapitalrendite: 1345Die Eigenkapitalrendite des Unternehmens (12.7%) wird als niedrig angesehen.